Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT06339424 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma(PhotonAB) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06379256 |
| Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy |
| recruiting |
| — |
| 300 |
| Chang Gung Memorial HospitalOTHER |
| 1 |
| May 14, 2025 |
| clinicaltrials |
| NCT06383520 | Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma | recruiting | Early Phase 1 | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06911255 | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 24 | Yoon Jun KimOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05409482 | A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma | recruiting | — | 300 | Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06961526 | Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab | recruiting | N/A | 110 | Tanta UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06961617 | Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06960863 | Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma | recruiting | — | 80 | Tanta UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06420440 | Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | recruiting | Phase 2 | 160 | Chen XiaopingOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06950827 | Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma | recruiting | — | 400 | West China HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT06904196 | Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC | recruiting | Phase 2 | 78 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06418659 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients | recruiting | Early Phase 1 | 37 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06940102 | Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors | recruiting | — | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06909708 | SIRT Versus cTACE for Unresectable HCC (CHANCE2506) | recruiting | N/A | 108 | Zhongda HospitalOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05687747 | Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma | recruiting | Phase 1 | 100 | National University Hospital, SingaporeOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05828446 | Improving Hepatocellular Carcinoma Screening(AMRIK) | recruiting | N/A | 330 | Naik Vietti VioliOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06898398 | TACE Combined Surgery for the Resectable Huge HCC | recruiting | — | 326 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06899854 | Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer. | recruiting | — | 53 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06905262 | Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt) | recruiting | — | 70 | National Cancer Institute, NaplesOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06382103 | Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy | recruiting | — | 240 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06641713 | HAIC Compared With TACE in Huge Hepatocellular Carcinoma | recruiting | — | 664 | Sun Yat-sen UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03612726 | The Overall Survival of Patients With Unresectable HCC in Real-life | recruiting | — | 5,000 | Humanity & Health Medical Group LimitedOTHER | 3 | Mar 24, 2025 | clinicaltrials |
| NCT03899428 | Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | recruiting | Phase 2 | 30 | Humanity & Health Medical Group LimitedOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06876753 | Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC(CHANCE2421) | recruiting | — | 300 | Zhongda HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | recruiting | Phase 3 | 570 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06864221 | Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma | recruiting | — | 260 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06873269 | Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma(TARE for HCC) | recruiting | — | 100 | Universitair Ziekenhuis BrusselOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03895359 | Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma(TACE) | recruiting | Phase 3 | 128 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04745390 | Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer(SAVIOR) | recruiting | N/A | 110 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06870942 | Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06742892 | A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | recruiting | Phase 2 | 90 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06864195 | A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions(VOCAL2) | recruiting | — | 750 | Imperial College LondonOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | recruiting | Phase 1 | 80 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05057845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05992220 | Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion(ALERT-HCC) | recruiting | Phase 2 | 138 | Asan Medical CenterOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06397235 | DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC | recruiting | Phase 2 | 130 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC(P-HCC-CVL) | recruiting | Phase 4 | 120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06821958 | Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF) | recruiting | N/A | 36 | Charite University, Berlin, GermanyOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05520788 | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing(CCGLC-006) | recruiting | — | 200 | Tongji HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | recruiting | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | recruiting | N/A | 234 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05596630 | Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC | recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06542796 | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma | recruiting | N/A | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06813508 | Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH(BOMASH) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2025source: clinicaltrials